ten23 health Opens State-of-the-Art VIVA2® Sterile Manufacturing Facility in Visp
Share this article
This advanced, energy-efficient plant will enhance the company’s capabilities in commercial and clinical manufacturing of sterile medicines, including vials, syringes, and cartridges.
The Swiss CDMO celebrates the grand opening of its VIVA2® facility in Visp. The facility adds two production lines: Line 2, designed for large-scale filling of ready-to-use containers, and Line 3, which handles clinical to commercial vial filling with freeze-drying capabilities. Combined, these lines can produce 30 to 70 million units annually, utilizing advanced robotics and Glass C isolator technology to ensure precise, high-quality sterile fills.
VIVA2® is energy-efficient, generating surplus power via a solar panel-covered façade, and contributes to the local economy by creating jobs. The opening ceremony featured industry leaders, collaboration partners, and local officials.
“/ am proud and excited about the VIVA2® Facility Grand Opening. This is the start of something great, and VIVA2’s capabilities for sterile manufacturing will be a key opportunity to supply essential medicines to patients,” said Prof. Dr. Hanns-Christian Mahler, CEO of ten23 health.
About ten23 health
Headquartered in Basel and Visp, ten23 health is a CDMO specializing in developing, manufacturing, and testing injectable medicines. The company is committed to sustainability and innovation in healthcare, backed by 3i Group, an equity partner.
Source: Press release
📸 ten23 health